LT4982B - N-heterocikliniai dariniai kaip nos inhibitoriai - Google Patents

N-heterocikliniai dariniai kaip nos inhibitoriai Download PDF

Info

Publication number: LT4982B
Authority: LT; Lithuania
Prior art keywords: amino; imidazol; methylpyrimidin; acetamide; ethyl
Prior art date: 1999-08-26

Application number

LT2002028A

Other languages

English (en)

Lithuanian (lt)

Other versions

LT2002028A (en

Inventor

Damian O. Arnaiz

John J. Baldwin

David D. Davey

James J. Devlin

Roland Ellwood Dolle Iii

Bin Ye

Gary B. Phillips

Gonghua Pan

John Parkinson

Kirk Mcmillan

Michael H.J. Ohlmeyer

Michael M. Morrissey

Shawn David Erickson

Vidyadhar Madhav Paradkar

Zuchun Zhao

Original Assignee

Berlex Laboratories,Inc.

Pharmacopeia,Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-26

Filing date

2002-03-15

Publication date

2003-01-27

2002-03-15 Application filed by Berlex Laboratories,Inc., Pharmacopeia,Inc. filed Critical Berlex Laboratories,Inc.

2002-09-25 Publication of LT2002028A publication Critical patent/LT2002028A/xx

2003-01-27 Publication of LT4982B publication Critical patent/LT4982B/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Cardiology (AREA)
Immunology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

LT2002028A 1999-08-26 2002-03-15 N-heterocikliniai dariniai kaip nos inhibitoriai LT4982B (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/383,813 US6432947B1 (en)	1997-02-19	1999-08-26	N-heterocyclic derivatives as NOS inhibitors

Publications (2)

Publication Number	Publication Date
LT2002028A LT2002028A (en)	2002-09-25
LT4982B true LT4982B (lt)	2003-01-27

Family

ID=23514822

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LT2002028A LT4982B (lt)	1999-08-26	2002-03-15	N-heterocikliniai dariniai kaip nos inhibitoriai

Country Status (34)

Country	Link
US (11)	US6432947B1 (xx)
EP (1)	EP1206467B1 (xx)
JP (1)	JP4739625B2 (xx)
KR (1)	KR100708783B1 (xx)
CN (1)	CN1206228C (xx)
AT (1)	ATE256681T1 (xx)
AU (1)	AU769405B2 (xx)
BG (1)	BG65804B1 (xx)
BR (1)	BR0014144A (xx)
CA (1)	CA2376355C (xx)
CZ (1)	CZ2002642A3 (xx)
DE (1)	DE60007329T2 (xx)
DK (1)	DK1206467T3 (xx)
EE (1)	EE05199B1 (xx)
ES (1)	ES2213599T3 (xx)
HK (1)	HK1043594A1 (xx)
HR (1)	HRP20020175B1 (xx)
HU (1)	HUP0202450A3 (xx)
IL (2)	IL148313A0 (xx)
LT (1)	LT4982B (xx)
LV (1)	LV12887B (xx)
MX (1)	MXPA02002022A (xx)
NO (1)	NO323886B1 (xx)
NZ (1)	NZ517411A (xx)
PL (1)	PL353539A1 (xx)
PT (1)	PT1206467E (xx)
RO (1)	RO122202B1 (xx)
RS (1)	RS50378B (xx)
RU (1)	RU2277094C2 (xx)
SI (1)	SI20818B (xx)
SK (1)	SK2622002A3 (xx)
UA (1)	UA72930C2 (xx)
WO (1)	WO2001014371A1 (xx)
ZA (1)	ZA200201485B (xx)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6432947B1 (en) *	1997-02-19	2002-08-13	Berlex Laboratories, Inc.	N-heterocyclic derivatives as NOS inhibitors
HRP990246A2 (en) *	1998-08-07	2000-06-30	Du Pont Pharm Co	Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ509241A (en)	1998-08-07	2003-08-29	Du Pont Pharm Co	Succinoylamino lactams as inhibitors of alpha-beta protein production
AU777735B2 (en) *	1999-07-15	2004-10-28	Pharmacopeia, Inc.	Bradykinin B1 receptor antagonists
GB2361473C (en) *	2000-03-08	2005-06-28	Microgenics Corp	Ecstasy-class analogs and use of same in detection of ecstasy-class compounds
EP1268433A1 (en) *	2000-04-03	2003-01-02	Bristol-Myers Squibb Pharma Company	Cyclic lactams as inhibitors of a-beta-protein production
US20030055249A1 (en) *	2001-07-17	2003-03-20	Fick David B.	Synthesis and methods of use of pyrimidine analogues and derivatives
US7778711B2 (en) *	2001-08-31	2010-08-17	Bio Control Medical (B.C.M.) Ltd.	Reduction of heart rate variability by parasympathetic stimulation
US7885709B2 (en) *	2001-08-31	2011-02-08	Bio Control Medical (B.C.M.) Ltd.	Nerve stimulation for treating disorders
US7904176B2 (en)	2006-09-07	2011-03-08	Bio Control Medical (B.C.M.) Ltd.	Techniques for reducing pain associated with nerve stimulation
US8571653B2 (en) *	2001-08-31	2013-10-29	Bio Control Medical (B.C.M.) Ltd.	Nerve stimulation techniques
EP1795192A3 (en) *	2002-04-30	2008-05-07	Bayer Schering Pharma Aktiengesellschaft	1-(Pyridazin-3-yl)-imidazole derivatives as inhibitors of nitric oxide synthase (NOS)
US6982259B2 (en) *	2002-04-30	2006-01-03	Schering Aktiengesellschaft	N-heterocyclic derivatives as NOS inhibitors
AU2003260033A1 (en) *	2002-08-29	2004-03-19	Schering Aktiengesellschaft	Methods of treating acute respiratory distress syndrome
JP2006506366A (ja) *	2002-10-18	2006-02-23	ファイザー・プロダクツ・インク	カンナビノイド受容体リガンドおよびその使用方法
WO2005080371A1 (en) *	2004-02-12	2005-09-01	Merck & Co., Inc.	Amino heterocyclic modulators of chemokine receptor activity
EP1568698A1 (en) *	2004-02-27	2005-08-31	Aventis Pharma Deutschland GmbH	Pyrrole-derivatives as factor Xa inhibitors
KR100935273B1 (ko) *	2004-06-10	2010-01-06	아이알엠 엘엘씨	단백질 키나제 억제제 화합물 및 조성물
EP1758892B1 (en) *	2004-06-10	2012-10-17	Irm Llc	Compounds and compositions as protein kinase inhibitors
WO2006034473A2 (en) *	2004-09-23	2006-03-30	Reddy Us Therapeutics, Inc.	Novel pyrimidine compounds, process for their preparation and compositions containing them
UY29177A1 (es) *	2004-10-25	2006-05-31	Astex Therapeutics Ltd	Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) *	2004-10-25	2020-10-26	Cancer Research Tech Ltd	Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
RU2007122485A (ru) *	2004-11-17	2008-12-27	Мийкана Терапьютикс	Ингибиторы киназы
US20070123572A1 (en) *	2005-11-28	2007-05-31	Kalypsys, Inc.	Novel method of preparation of 5-chloro-3-imidazol-1-yl-[1,2,4]thiadiazole and (3-imidazol-1-yl-[1,2,4]thiadiazol-5yl)-dialkyl-amines
BRPI0518096A (pt) *	2004-12-01	2008-10-28	Kalypsys Inc	composto, composição farmacêutica, uso de um composto para a preparação de um medicamento para o tratamento de uma condição resultante de uma anormalidade na produção de óxido nìtrico, uso de um composto para a preparação de um medicamento para o tratamento da dor em um indivìduo com necessidade do mesmo e uso de um composto para a preparação de um medicamento para o tratamento de inibição da dimerização de inos
KR101155335B1 (ko) *	2005-01-07	2012-06-11	엘지전자 주식회사	이동통신 단말기의 멀티미디어 메시지 동작방법
US7884109B2 (en) *	2005-04-05	2011-02-08	Wyeth Llc	Purine and imidazopyridine derivatives for immunosuppression
MX2007012393A (es) *	2005-04-05	2008-02-22	Pharmacopeia Inc	Derivados de purina e imidazopiridina para la inmunosupresion.
US7812025B2 (en) *	2005-08-12	2010-10-12	Takeda Pharmaceutical Company Limited	Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
AU2006297120B2 (en) *	2005-09-30	2011-05-19	Miikana Therapeutics, Inc.	Substituted pyrazole compounds
EP1954694A1 (en) *	2005-11-28	2008-08-13	Kalypsys, Inc.	Imidazole derivatives as nitric oxide synthase dimerisation inhibitor
US7989459B2 (en) *	2006-02-17	2011-08-02	Pharmacopeia, Llc	Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US20090281075A1 (en) *	2006-02-17	2009-11-12	Pharmacopeia, Inc.	Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US8017612B2 (en) *	2006-04-18	2011-09-13	Japan Tobacco Inc.	Piperazine compound and use thereof as a HCV polymerase inhibitor
JP5606734B2 (ja) *	2006-04-25	2014-10-15	アステックス、セラピューティックス、リミテッド	医薬化合物
JP2009534454A (ja) *	2006-04-25	2009-09-24	アステックス、セラピューティックス、リミテッド	医薬化合物
SI2497500T1 (sl)	2006-10-03	2017-01-31	Genzyme Corporation	Genska terapija za spinalno mišično atrofijo
CL2007002867A1 (es) *	2006-10-04	2008-06-27	Pharmacopeia Inc	Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras.
US7902187B2 (en) *	2006-10-04	2011-03-08	Wyeth Llc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7919490B2 (en) *	2006-10-04	2011-04-05	Wyeth Llc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US20080119496A1 (en) *	2006-11-16	2008-05-22	Pharmacopeia Drug Discovery, Inc.	7-Substituted Purine Derivatives for Immunosuppression
EP1939181A1 (en) *	2006-12-27	2008-07-02	sanofi-aventis	Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
EP2166849A4 (en) *	2007-06-11	2010-09-15	Miikana Therapeutics Inc	SUBSTITUTED PYRAZOL COMPOUNDS
JP4705695B2 (ja)	2007-10-11	2011-06-22	アストラゼネカアクチボラグ	プロテインキナーゼｂ阻害剤としてのピロロ［２，３−ｄ］ピリミジン誘導体
JP2011510998A (ja) *	2008-01-30	2011-04-07	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	新規ｓＥＨ阻害剤およびその使用
JP2011510996A (ja) *	2008-01-30	2011-04-07	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	新規ｓＥＨ阻害剤およびその使用
US20100311775A1 (en) *	2008-01-30	2010-12-09	Smithkline Beecham Corporation	Novel sEH Inhibitors and Their Use
WO2009120094A2 (en) *	2008-03-27	2009-10-01	Auckland Uniservices Limited	Substituted pyrimidines and triazines and their use in cancer therapy
GB0908394D0 (en)	2009-05-15	2009-06-24	Univ Leuven Kath	Novel viral replication inhibitors
GB0913636D0 (en)	2009-08-05	2009-09-16	Univ Leuven Kath	Novel viral replication inhibitors
WO2011034470A1 (en)	2009-09-18	2011-03-24	Volvo Lastvagnar Ab	Console for attachment to a vehicle chassis and vehicle comprising a suspension carrying console
JP2013542243A (ja)	2010-11-15	2013-11-21	カトリーケウニヴェルシテイトルーヴェン	新規な抗ウイルス性化合物
CN102617503B (zh) *	2011-03-03	2014-05-07	上海常丰生物医药科技有限公司	(s)-3-吗啉基羧酸的合成方法
PH12013502048B1 (en)	2011-04-01	2018-07-11	Astrazeneca Ab	Therapeutic treatment
AU2012321110B2 (en)	2011-11-30	2014-10-23	Astrazeneca Ab	Combination treatment
AU2013204533B2 (en)	2012-04-17	2017-02-02	Astrazeneca Ab	Crystalline forms
US9701661B2 (en) *	2014-07-11	2017-07-11	Northwestern University	2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
GB201512635D0 (en)	2015-07-17	2015-08-26	Ucl Business Plc	Uses of therapeutic compounds
KR102220971B1 (ko)	2016-12-20	2021-02-25	아스트라제네카 아베	아미노-트리아졸로피리딘 화합물 및 암 치료에서의 이의 용도
CN107115334A (zh) *	2017-03-04	2017-09-01	王宏	一种治疗免疫性流产的药物组合物
US11535660B1 (en)	2018-03-23	2022-12-27	Cannot Therapeutics, Inc.	Modulators of G-protein coupled receptors
EP3628669A1 (en)	2018-09-28	2020-04-01	GenKyoTex Suisse SA	Novel compounds as nadph oxidase inhibitors
MX2023013492A (es)	2021-05-13	2024-02-29	Carmot Therapeutics Inc	Moduladores de los receptores acoplados a proteinas g.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6339875A (ja)	1986-08-05	1988-02-20	Nissin Food Prod Co Ltd	ピリミジン誘導体
DE4118720A1 (de)	1991-06-07	1992-12-10	Bayer Ag	Substituierte imidazolinylpyrimidine
TW212798B (xx) *	1991-11-25	1993-09-11	Takeda Pharm Industry Co Ltd
DE69322076D1 (de) *	1992-02-28	1998-12-17	Zenyaku Kogyo Kk	S-triazin-derivate und diese als aktiven wirkstoff enthaltende heilmittel gegen östrogen abhängige krankheiten
TW279864B (xx) *	1993-02-19	1996-07-01	Janssen Pharmaceutica Nv
US5593992A (en)	1993-07-16	1997-01-14	Smithkline Beecham Corporation	Compounds
DK0640599T3 (da)	1993-08-26	1998-09-28	Ono Pharmaceutical Co	4-Aminopyrimidin-derivater
US5426110A (en)	1993-10-06	1995-06-20	Eli Lilly And Company	Pyrimidinyl-glutamic acid derivatives
WO1996014842A1 (en)	1994-11-15	1996-05-23	Merck & Co., Inc.	Substituted heterocycles as inhibitors of nitric oxide synthase
US5629322A (en)	1994-11-15	1997-05-13	Merck & Co., Inc.	Cyclic amidine analogs as inhibitors of nitric oxide synthase
EP0874846B1 (en) *	1995-11-01	2003-04-02	Novartis AG	Purine derivatives and processes for their preparation
ZA977427B (en)	1996-09-04	1998-03-02	Dainippon Pharmaceutical Co	2,4-disubstituted pyrimidine derivative, process for preparing the same, and a pharmaceutical composition containing the same.
US6432947B1 (en) *	1997-02-19	2002-08-13	Berlex Laboratories, Inc.	N-heterocyclic derivatives as NOS inhibitors
CN1100777C (zh) *	1997-02-19	2003-02-05	伯莱克斯实验室公司	作为nos抑制剂的n－杂环衍生物
AU725548B2 (en) *	1997-03-11	2000-10-12	E.I. Du Pont De Nemours And Company	Heteroaryl azole herbicides
US6525051B2 (en)	2000-03-27	2003-02-25	Schering Aktiengesellschaft	N-heterocyclic derivatives as NOS inhibitors

1999
- 1999-08-26 US US09/383,813 patent/US6432947B1/en not_active Expired - Fee Related
2000
- 2000-08-24 BR BR0014144-5A patent/BR0014144A/pt not_active Application Discontinuation
- 2000-08-24 CA CA002376355A patent/CA2376355C/en not_active Expired - Fee Related
- 2000-08-24 CN CNB008146691A patent/CN1206228C/zh not_active Expired - Fee Related
- 2000-08-24 EP EP00959333A patent/EP1206467B1/en not_active Expired - Lifetime
- 2000-08-24 KR KR1020027002407A patent/KR100708783B1/ko not_active Expired - Fee Related
- 2000-08-24 WO PCT/US2000/023173 patent/WO2001014371A1/en not_active Ceased
- 2000-08-24 HK HK02105317.3A patent/HK1043594A1/zh unknown
- 2000-08-24 HU HU0202450A patent/HUP0202450A3/hu unknown
- 2000-08-24 HR HR20020175A patent/HRP20020175B1/xx not_active IP Right Cessation
- 2000-08-24 UA UA2002032401A patent/UA72930C2/uk unknown
- 2000-08-24 AT AT00959333T patent/ATE256681T1/de not_active IP Right Cessation
- 2000-08-24 MX MXPA02002022A patent/MXPA02002022A/es active IP Right Grant
- 2000-08-24 RU RU2002107203/04A patent/RU2277094C2/ru not_active IP Right Cessation
- 2000-08-24 DE DE60007329T patent/DE60007329T2/de not_active Expired - Lifetime
- 2000-08-24 NZ NZ517411A patent/NZ517411A/en unknown
- 2000-08-24 SK SK262-2002A patent/SK2622002A3/sk unknown
- 2000-08-24 RS YUP-120/02A patent/RS50378B/sr unknown
- 2000-08-24 ES ES00959333T patent/ES2213599T3/es not_active Expired - Lifetime
- 2000-08-24 DK DK00959333T patent/DK1206467T3/da active
- 2000-08-24 PL PL00353539A patent/PL353539A1/xx not_active Application Discontinuation
- 2000-08-24 RO ROA200200205A patent/RO122202B1/ro unknown
- 2000-08-24 CZ CZ2002642A patent/CZ2002642A3/cs unknown
- 2000-08-24 SI SI200020040A patent/SI20818B/sl not_active IP Right Cessation
- 2000-08-24 IL IL14831300A patent/IL148313A0/xx active IP Right Grant
- 2000-08-24 PT PT00959333T patent/PT1206467E/pt unknown
- 2000-08-24 AU AU70671/00A patent/AU769405B2/en not_active Ceased
- 2000-08-24 JP JP2001518702A patent/JP4739625B2/ja not_active Expired - Fee Related
- 2000-08-24 EE EEP200200091A patent/EE05199B1/xx not_active IP Right Cessation
2002
- 2002-02-21 IL IL148313A patent/IL148313A/en not_active IP Right Cessation
- 2002-02-21 ZA ZA200201485A patent/ZA200201485B/en unknown
- 2002-02-26 BG BG106440A patent/BG65804B1/bg unknown
- 2002-02-26 NO NO20020925A patent/NO323886B1/no not_active IP Right Cessation
- 2002-03-15 LT LT2002028A patent/LT4982B/lt not_active IP Right Cessation
- 2002-03-26 LV LVP-02-50A patent/LV12887B/en unknown
- 2002-04-12 US US10/121,212 patent/US6849739B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,808 patent/US6670473B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,682 patent/US20030073669A1/en not_active Abandoned
- 2002-04-12 US US10/122,047 patent/US6887865B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,886 patent/US6841673B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/122,006 patent/US6864368B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,659 patent/US6864263B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/122,072 patent/US6841674B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,758 patent/US6846829B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,379 patent/US6747031B2/en not_active Expired - Fee Related

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AOYAMA Y ET AL.: "Inhibition by a novel azole antifungal agent with a geranyl group on lanosterol 14 alpha-demethylase of yeast", BIOCHEM PHARMACOL., 1992, pages 1701 - 1705
CHABIN RM ET AL.: "Active-site structure analysis of recombinant human inducible nitric oxide synthase using imidazole", BIOCHEMISTRY, 1996, pages 9567 - 9575
CHWALISZ, K. ; BUHIMSCHI, I. ; GARFIELD, R. E: "Role of nitric oxide in obstetrics", PERINATAL AND NEONATAL MEDICINE, 1996, pages 292 - 329
D. CORY ADAMSON ET AL.: "Immunologic NO Synthase: Elevation in Severe AIDS Dementia and Induction by HIV-1 gp41", SCIENCE, 1996, pages 1917 - 1921
H. MICHAEL BELMONT MD ET AL.: "Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus", ARTHRITIS AND RHEUMATISM, 1997, pages 1810 - 1816
HUNOT S ET AL.: "Nitric oxide synthase and neuronal vulnerability in Parkinsons disease", NEUROSCIENCE. 1996 MAY;72(2):355-63. NITRIC OXI, 1996, pages 355 - 3563
J B WEINBERG ET AL.: "The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally admi", J. EXP. MED, 1994, pages 651 - 660
J. NEUROSCI: "Delayed Reduction of Ischemic Brain Injury and Neurological Deficits in Mice Lacking the Inducible Nitric Oxide Synthase Gene", J. NEUROSCI., 1997, pages 9157 - 9164, XP000867073
MAURICE M ET AL.: "Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture", FASEB J., 1992, pages 752 - 758, XP002715403
PARKINSON JF, MITROVIC B, MERRILL JE.: "The role of nitric oxide in multiple sclerosis", J MOL MED (BERL), 1997, pages 174 - 186
SMITH, M.A. ET AL.: "Widespread peroxynitrite-mediated damage in Alzheimers disease", J. NEUROSCI., 1997, pages 2653 - 2657, XP002379310
WALLACE MN: "Nitric oxide synthase in reactive astrocytes adjacent to beta-amyloid plaques", EXP NEUROL., 1997, pages 266 - 272

Also Published As

Publication number	Publication date
CN1206228C (zh)	2005-06-15
US20030073669A1 (en)	2003-04-17
LT2002028A (en)	2002-09-25
JP2003507476A (ja)	2003-02-25
US20020165203A1 (en)	2002-11-07
EP1206467A1 (en)	2002-05-22
BG65804B1 (bg)	2009-12-31
US20030027794A1 (en)	2003-02-06
US6846829B2 (en)	2005-01-25
UA72930C2 (uk)	2005-05-16
US20030060452A1 (en)	2003-03-27
RU2277094C2 (ru)	2006-05-27
US6747031B2 (en)	2004-06-08
NZ517411A (en)	2003-09-26
ES2213599T3 (es)	2004-09-01
SK2622002A3 (en)	2002-09-10
LV12887B (en)	2003-01-20
US6887865B2 (en)	2005-05-03
DK1206467T3 (da)	2004-04-26
HK1043594A1 (zh)	2002-09-20
KR100708783B1 (ko)	2007-04-19
NO20020925D0 (no)	2002-02-26
HUP0202450A2 (hu)	2002-11-28
AU769405B2 (en)	2004-01-29
PL353539A1 (en)	2003-12-01
ZA200201485B (en)	2003-07-30
US20030004137A1 (en)	2003-01-02
US20030078265A1 (en)	2003-04-24
IL148313A0 (en)	2002-09-12
HRP20020175A2 (en)	2005-10-31
US6864263B2 (en)	2005-03-08
US20030069210A1 (en)	2003-04-10
US20030092678A1 (en)	2003-05-15
CN1382136A (zh)	2002-11-27
WO2001014371A1 (en)	2001-03-01
YU12002A (sh)	2005-03-15
SI20818A (sl)	2002-08-31
ATE256681T1 (de)	2004-01-15
SI20818B (sl)	2009-04-30
CZ2002642A3 (cs)	2002-08-14
PT1206467E (pt)	2004-05-31
NO323886B1 (no)	2007-07-16
MXPA02002022A (es)	2002-10-31
HUP0202450A3 (en)	2003-12-29
US20030083332A1 (en)	2003-05-01
BR0014144A (pt)	2002-05-21
BG106440A (en)	2002-11-29
CA2376355A1 (en)	2001-03-01
RO122202B1 (ro)	2009-02-27
DE60007329T2 (de)	2004-06-09
US6864368B2 (en)	2005-03-08
HRP20020175B1 (hr)	2008-07-31
US6841673B2 (en)	2005-01-11
EE05199B1 (et)	2009-08-17
IL148313A (en)	2008-04-13
KR20020062277A (ko)	2002-07-25
US6432947B1 (en)	2002-08-13
NO20020925L (no)	2002-04-16
US6849739B2 (en)	2005-02-01
EE200200091A (et)	2003-04-15
US6841674B2 (en)	2005-01-11
EP1206467B1 (en)	2003-12-17
AU7067100A (en)	2001-03-19
JP4739625B2 (ja)	2011-08-03
HK1051683A1 (en)	2003-08-15
CA2376355C (en)	2009-10-27
RS50378B (sr)	2009-11-10
US20020183323A1 (en)	2002-12-05
US6670473B2 (en)	2003-12-30
DE60007329D1 (de)	2004-01-29

Publication	Publication Date	Title
LT4982B (lt)	2003-01-27	N-heterocikliniai dariniai kaip nos inhibitoriai
ES2292488T3 (es)	2008-03-16	Derivados de la urea, como agentes antiinflamatorios.
DE69612949T2 (de)	2001-09-20	Neue benzimidazolderivate mit cgmp-phosphodiesterase inhibierender wirkung
EA007062B1 (ru)	2006-06-30	Новые дигидроптеридиноны, способы их получения и их применение в качестве лекарственных средств
KR20090036573A (ko)	2009-04-14	신규한 피리딘 유사체
CA2453147A1 (en)	2003-01-23	Methods of treating cytokine mediated diseases
KR20010080599A (ko)	2001-08-22	아미노피라졸 유도체
KR20090031605A (ko)	2009-03-26	신규한 피리딘 유사체
EP1567507B1 (en)	2006-06-14	1,2,3- triazole amide derivatives as cytokine inhibitors
US3169966A (en)	1965-02-16	Aminopyrazoles
CA2504213A1 (en)	2004-05-13	New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
JPH1067753A (ja)	1998-03-10	新規ベンゾイミダゾール、ベンゾオキサゾール及びベンゾチアゾール化合物、その製造方法、並びにそれを含有する医薬組成物
EA010392B1 (ru)	2008-08-29	Производные имидазолов, способ их получения и их применение в качестве лекарственного средства
BRPI1007902B1 (pt)	2022-01-04	Compostos de fenilmidazol
JPH10513172A (ja)	1998-12-15	５−ｈｔ▲下１ｄ▼受容体アゴニストとしての置換１，４−ピペラジン−ヘテロアリール誘導体
JP2008501775A (ja)	2008-01-24	オキシトシン拮抗剤としての置換トリアゾール誘導体
BG100209A (bg)	1996-07-31	Пиролохинолинонови производни с позитивна инотропна и лузитропна активност
US5356922A (en)	1994-10-18	Imidazole compounds, processes for their preparation, pharmaceuticals based on these compounds and some intermediates
JPH0971564A (ja)	1997-03-18	ベンズアミドオキシム誘導体及びその医薬用途
JPS606689A (ja)	1985-01-14	トリスアゾロ〔２，３−ｃ〕〔１，３〕ベンゾジアゼピン類、その製法およびそれを含む医薬組成物
JPWO1994026737A1 (ja)	1995-08-03	イミダゾリルキノキサリンジオン誘導体及びその医薬組成物

Legal Events

Date	Code	Title	Description
2011-04-26	MM9A	Lapsed patents	Effective date: 20100824